Figure 5.

Transcriptomic analysis of PPARδ and PPARγ activation in 3T3-L1 adipocytes. (a) Plot of PLS-DA scores showing the clustering of gene transcription in control and PPARδ agonist-treated 3T3-L1 adipocytes as measured with microarray analysis: PPARδ agonist-treated (filled circles; n = 6), control (filled squares; n = 6) (R²(X) = 35%, Q² = 90%). (b) Diagram showing the effect of PPARδ activation on the integration of the energy metabolism pathways of 3T3-L1 adipocytes based on the combination of results from the metabolomic, transcriptomic and stable isotope labeling studies. Red indicates an increase in concentration or expression in cells treated with the PPARδ selective agonist GW610742. Blue indicates a decrease in concentration in cells treated with the PPARδ selective agonist GW610742. (c) Plot of PLS-DA scores showing the clustering of gene transcription in control and PPARγ agonist-treated 3T3-L1 adipocytes as measured with microarray analysis: PPARγ agonist-treated (filled circles; n = 6), control (filled squaresl n = 6) (R²(X) = 42%, Q² = 84%).